ENTITY

Oryzon Genomics (ORY SM)

58
Analysis
Health CareSpain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
bullishOryzon Genomics
16 Dec 2022 19:56Issuer-paid

Oryzon Genomics - Lead asset granted expansion into combo therapies

Oryzon Genomics has announced that it has been awarded an EU grant to initiate a project to investigate the company’s lead clinical oncology asset,...

Share
bullishOryzon Genomics
13 Dec 2022 16:18Issuer-paid

Oryzon Genomics - Positive ALICE readouts pave way in AML

Oryzon Genomics has presented the top-line results of its Phase IIa ALICE trial investigating its lead oncology LSD1 inhibitor iadademstat in...

Share
bullishOryzon Genomics
09 Nov 2022 20:08Issuer-paid

Oryzon Genomics - IND granted for collaborative Phase II trial

Oryzon Genomics announced that it has received FDA investigational new drug (IND) approval for the initiation of a collaborative Phase II trial...

Share
bullishOryzon Genomics
03 Nov 2022 19:00Issuer-paid

Oryzon Genomics - Clinical ramp in Q3; several catalysts approaching

Oryzon Genomics reported Q322 results that are largely in line with our expectations. The clinical ramp up of its key assets, iadademstat and...

Share
bullishOryzon Genomics
16 Sep 2022 18:38Issuer-paid

Oryzon Genomics - Encouraging safety data in PORTICO

Oryzon Genomics has announced promising preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial at the 10th European...

Share
x